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Assessment of the severity of atopic dermatitis (AD) is necessary to evaluate the disease process. This study evaluates and validates
the TIS in children with AD presenting in general practice. Independent investigators determined the severity of AD using the
TIS and the objective SCORAD. The interobserver agreement for the TIS and SCORAD was calculated, as was the correlation
between TIS and SCORAD. The mean time to assess the TIS was less than one minute. A moderate-to-good agreement between
the observers was found for the TIS (κ = 0.604 or 0.464), or SCORAD (κ = 0.695 or 0.700). There was an excellent correlation
b e t w e e nT I Sa n dS C O R A D( rs = 0.755–0.839). In conclusion, the TIS is an easy and fast method to score AD. Because of the
moderate to good interobserver agreement and the high correlation with the SCORAD, we recommend the TIS to determine the
severity of AD in general practice.
Copyright © 2009 Marjolein G. Willemsen et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
It is important to determine the severity of atopic dermatitis
(AD) when assessing the course of the disease, for example,
beforeandaftertreatment[1]. Because there are no serologic
markers that accurately reﬂect AD, measurements and
severityareprimarilybasedonsignsandsymptoms[2].Valid
and reliable clinical outcome measures are prerequisites for
evidence-based practice [3].
Investigators can currently select from 20 diﬀerent
measurementsofADdiseaseseverity.Ofthese,onlytheEASI
(Eczema Area Severity Index) [4], POEM (patient-oriented
eczema measure) [5], and SCORAD (SCORing Atopic
Dermatitis) index [6, 7]h a v eb e e ns u ﬃciently validated to
recommend their use in clinical trials and everyday practice
[8].
The most widely used clinical scoring system is the SCO-
RAD index [7]. The SCORAD index (including six objective
items and two subjective issues) or the objective SCORAD
(SCORAD from now on, without subjective measures) is
an excellent system for clinical trials but is too complicated
and time consuming (scoring takes about 7–10 minutes per
patient) for a routine clinical setting. For this reason, the
Three Item Severity score (TIS), a simpliﬁed version of the
SCORAD, was developed [1, 9].
The TIS has been tested in a dermatology outpatient
department; a high correlation and a moderate-to-fair
interobserveragreementwerefoundbetweentheTISandthe
SCORAD [9]. The Dutch College of General Practitioners’
guideline on AD recommends treating patients according to
the severity of AD [11]. The guideline acknowledges that
the value of the TIS has not yet been established in general
practice and recommends more research in this area [11].
Therefore, the present study explored whether the TIS
is useful in children treated in general practice. For this,
we evaluated and validated the TIS, and calculated the
interobserver agreement for and the correlation between the
TIS and the SCORAD.2 Dermatology Research and Practice
Table 1: Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
– Aged 0–6 years – Chronic disease other than AD, asthma,
food intolerance, or allergic rhinitis
Patient selection
(computer search) – Diagnosis of AD by GP – Psychological problems which could
inﬂuence follow-up
– Had consultation for AD complaints within last 3 months or
repeated their prescriptions for AD treatment in last 3 months
– GP checked the selected patients and
could exclude patients
Telephone
questionnaire
– AD complaints at time of telephone questionnaire
(excoriations and skin lesions)
– Short-term illness at time of telephone
questionnaire
– Parent or caretaker unable to read or
write Dutch or English
First visit – Informed consent – Other skin conditions precluding
proper assessment of AD severity
– Diagnosis of AD using Williams’ criteria [10] – Short-term illness
AD: atopic dermatitis, GP: general practitioner.
Table 2: Classiﬁcation of the severity of atopic dermatitis for the SCORAD-index, the (objective) SCORAD, and Three Item Severity score
(TIS)±.
Instrument Classiﬁcation of severity of AD
Mild Moderate Severe
SCORAD-index 0–24 25–50 51–103
(Objective) SCORAD 0–14 15–40 41–83/93
TIS 0–2 3–5 6–9
±Adapted from Oranje et al. [1].
2.MaterialsandMethods
2.1. Patient Selection. This prospective study was conducted
in general practices in greater Rotterdam and a regional
Child Health Center (Renswoude area) between November
2007 and March 2008. Included were all patients with AD
under 7 years of age. The children were selected from the
computerized ﬁles of general practitioners (GPs). Children
were selected either by diagnosis, coded according to the
International Classiﬁcation of Primary Care (ICPC) [12], or
by prescribed medication, coded according to the Anatomi-
cal Therapeutic Chemical (ATC) classiﬁcation scheme [13].
Patients were selected using the ICPC code S87 (Atopic
Dermatitis), and/or ATC codes for topical treatment of
AD (zinc products, soft paraﬃn, and fat products, other
emollients and protectives, tars, topical corticosteroids, all
diﬀerent potencies), and according to the inclusion and
exclusion criteria (Table 1).
The study was approved by the ethics committee of Eras-
mus MC. All parents provided written informed consents to
participate in the study.
2.2. Materials. The SCORAD index consists of the interpre-
tation of the extent of the disorder, that is, the intensity,
composed of six items (erythema, oedema/papules, eﬀect of
scratching, oozing/crust formation, licheniﬁcation, and dry-
ness), and two subjective symptoms (itch and sleeplessness)
[1]; the maximum score is 103 points (Table 2).
In the SCORAD the subjective symptoms (itch and
sleeplessness) are not assessed; the total score is 83 points
(Table 2)[ 6]. “Bonus points” for disﬁguring lesions or func-
tional limiting lesions will receive 10 extra points (Table 2).
The TIS is the sum of the three items: erythema, oedema,
and excoriations (scored on a scale from 0 to 3); each item
should be scored on the most representative lesion, that is,
a lesion which represents the mean intensity for that item
(Table 2)[ 9] .T h eT I Si t e m sa r ei d e n t i c a lt ot h e i rS C O R A D
counterparts.
Two investigators (MW and RVV) were trained by a
pediatric dermatologist (APO) to complete the TIS and
SCORAD. To assess interobserver variability, both inves-
tigators determined the severity of AD in all children
simultaneously using the TIS and SCORAD. As a third
observer, a GP (PDM) simultaneously scored a subset of
patients.
Duringtheexamination,theobserversscoredtheseverity
of AD using ﬁrst the TIS and then using the SCORAD.
To assess usability of the TIS the observers recorded the
time required to assess the total TIS per patient.
All patients were observed at 3- to 4-week intervals, and
digital images of the most representative lesions were made
in all patients.
Because the symptoms of AD can ﬂuctuate greatly,
all the observers examined the patients during the same
visit; during each examination, the other observers were
in a separate room. The results of each examination were
immediately stored in a sealed envelope, ensuring that the
other observers were unaware of these results. The envelopes
remained sealed until the last observer had examined the
patients for the second time.Dermatology Research and Practice 3
Table 3: Interobserver agreement for the TIS (categorized into mild, moderate, or severe).
First visit (n = 66) Second visit (n = 65)
Observer 1 versus 2 κ = 0.562 κ = 0.464
Weighted κ = 0.604 Weighted κ = 0.464
First visit (n = 16) Second visit (n = 15)
3o b s e r v e r s κ = 0.758 κ = 0.481
2.3. Statistical Analysis. The total scores of the TIS and
SCORAD were calculated per patient for each observer. The
total scores of the TIS (0–9) and the SCORAD (0–83/93)
werethencategorizedintothreegroups:mild,moderate,and
severe. We chose to categorize the scores into these groups
since treatment of AD is based on this classiﬁcation. The
scores were categorized as shown in Table 2.
Statistical analysis was performed with SPSS version 15
(SPSS Inc, Chicago) and STATA version 10 (StataCorp, Col-
legeStation).InterobserveragreementforboththeSCORAD
and TIS (categorized scores) was calculated using Cohen’s
kappa. Agreement for each item separately (licheniﬁcation,
oozing/crusts, dryness, erythema, oedema/populations, and
excoriations) was also calculated using Cohen’s kappa. We
consider an agreement between the observers above 0.75 as
an excellent agreement and below 0.40 as a poor agreement;
results between 0.4 and 0.75 were regarded as fair to good
[14]. Agreement regarding the extent of the disease was
calculated with the intraclass correlation coeﬃcient (ICC).
The correlation between the TIS and SCORAD (uncat-
egorized scores) was calculated using Spearman’s rank cor-
relation. The correlation between the categorized SCORAD
(i.e., classiﬁcation into mild, moderate, and severe) and
categorized TIS was calculated using the ICC.
The correlations between SCORAD (the uncatego-
rized scores) and the diﬀerent items (licheniﬁcation, ooz-
ing/crusts, dryness, erythema, oedema/papulations, excori-
ations, and the extent) and between the TIS (the uncatego-
rized scores) and the three items (erythema, oedema/popu-
lations, and excoriations) were calculated using Spearman’s
rank correlation.
3. Results
3.1. Study Population. A total of 45 GPs agreed to participate
in the study. A total of 278 patients with an age below
7 years and with a history of AD (ICPC S87) or use of
medical treatment for AD were selected in the database
of the GP. These selected patients were invited by mail to
participate. Of these, 89 had self-reported complaints of AD
at the moment and were willing to participate. Finally 66
patients were included in the study. Twenty three children
were excluded for the following reasons: 12 had no AD
complaints at the time of inclusion, 3 parents were unable to
ﬁllintheconsentformsandanother8wereexcludedbecause
their answer forms were received after the inclusion period
had closed. Thus, the ﬁnal study population consisted of 66
patients (57.6% girls, mean age of 31 months—range 0.5–83
months). Of these, 50 were examined by two observers and
16 by three observers. All 66 patients were available for the
ﬁrst visit, and 65 patients were observed during the second
visit.
3.2. Severity of AD. The mean TIS scores were 2.1 (SD = 1.1,
determined at the ﬁrst visit) and 1.8 (SD = 1.0, at the second
visit). The mean SCORAD scores were 13.5 (SD = 8.7) at
the ﬁrst visit and 11.9 (SD = 7.8) at the second visit. The
severity of AD was predominantly mild, accounting for 73%
of the cases according to the TIS (score 0–2) and for 70%
of the cases according to the SCORAD (0–14). Moderate AD
accountedfor24.6%accordingtotheTIS(score3–5)andfor
27.6% according to the SCORAD (score 15–40). Severe AD
accounted for 2.4% in both scoring systems.
3.3. Evaluation of the TIS and SCORAD. The mean time to
assess the TIS per patient was 43 seconds (range 7–170).
Moderate-to-good interobserver agreement (weighted κ =
0.604 for visit 1 and 0.464 for visit 2) was found between the
two observers for the categorized TIS (i.e., severity classiﬁed
into mild, moderate, and severe). Similar results were found
in a smaller group where patients were observed by three
observers (Table 3).
For the SCORAD (categorized into mild, moderate, and
severe) the interobserver agreement also showed a good
agreement (κ = 0.665 for ﬁrst visit and κ = 0.776 for second
visit).
3.4. Correlation between the TIS and SCORAD. We calcu-
lated the correlation between the TIS and SCORAD. For all
three observers for both visits, a good correlation was found
between the two scoring methods (Table 4, Figures 1(a) and
1(b)). The correlation between the categorized TIS (i.e.,
severity classiﬁed into mild, moderate, and severe, Table 2)
andcategorizedSCORAD(sameclassiﬁcation)wasalsogood
or excellent for all observers at both visits (rs = 0.637 to
0.985; P = .01; ICCs 0.622 to 0.933).
3.5. Correlation between Separate Intensity Items and TIS or
SCORAD. The correlation between the TIS and the separate
intensity items (erythema, oedema, and excoriations) was
calculated. For all observers, all intensity items correlated
well with the TIS (rs 0.611–0.980 for erythema; 0.604–
0.838 for oedema; 0.639–0.860 for excoriations). The items
erythema,oedema,andexcoriationsalsocorrelatedwellwith
the SCORAD for all observers (rs from 0.495 to 0.826).
Regarding the other items of the SCORAD, the items dryness
and extent showed a moderate-to-good correlation with the
SCORAD for all observers (rs 0.324 to 0.855 for dryness and
0.697 to 0.963 for extent). Only the items oozing/crusts and4 Dermatology Research and Practice
Table 4: Correlation between TIS and SCORAD.
First visit (n = 66) Second visit (n = 65)
Observer 1; TIS versus SCORAD rs = 0.807 (P = .01) rs = 0.755 (P = .01)
Observer 2; TIS versus SCORAD rs = 0.791 (P = .01) rs = 0.839 (P = .01)
First visit (n = 16) Second visit (n = 15)
Observer 3; TIS versus SCORAD rs = 0.809 (P = .01) rs = 0.791 (P = .01)
rs, Spearman’s rank.
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Figure 1: Correlation between TIS and SCORAD. Observations
from the two independent observers (obs 1 and 2) are displayed in
one ﬁgure ((a) ﬁrst visit, (b) second visit).
licheniﬁcation showed a weak correlation with the SCORAD
(rs from 0.197 to 0.638).
3.6. Interobserver Agreement on Separate Intensity Items.
The interobserver agreement for the separate intensity
items showed highly variable kappa values. Only the item
“erythema” showed a fair-to-good agreement between the
observers(κ = 0.603or0.621).Alsoagoodagreementforthe
item “extent” (item A of the SCORAD) was found between
the observers (ICC 0.761 and 0.857, for visit 1 and 2, resp.).
4. Discussion
In the present study a moderate-to-good interobserver
agreement was found between the observers for the TIS. The
overall agreement between observers was suﬃciently good to
recommend use of the TIS to assess the severity of AD in
generalpractice.TheTISisasimplemethodtodeterminethe
severity of AD, and assessment of the total TIS took about 43
seconds per patient. Therefore, the TIS is suitable for use in
dailypractice.Becauseagoodcorrelationwasfoundbetween
the TIS and the diﬀerent intensity items, we conclude
that these items (erythema, oedema, and excoriations) are
suitable determinants to evaluate the severity of AD with the
TIS.
In accordance with other studies [1, 9], we found a good
correlation between the TIS and SCORAD. The classiﬁcation
of the severity of AD into mild, moderate, and severe
also showed good correlations, but were lower than the
uncategorized scores. A possible explanation is that these
categorized scores were rearranged on an arbitrary line.
Thereby, some patients had a diﬀerence of only one point
between the two observers on the TIS, but were placed in
ad i ﬀerent category (mild, moderate, or severe). When the
patient scores were uncategorized, these minor diﬀerences
between the observers had no inﬂuence on the calculated
correlation;therefore,thesecorrelationscoresarehigher.The
highcorrelationbetweenTISandSCORADisnotsurprising,
because the TIS is a simpliﬁed version of the SCORAD.
For the SCORAD, a good interobserver agreement was
foundbetweenallobservers.Similartoclinicaltrialsinwhich
good interobserver agreement for the SCORAD has been
established [1, 9], the SCORAD also showed good agreement
in our general practice patients. We conclude that, although
SCORAD is an eﬀective scoring system and is suitable to
determine the severity of AD in clinical trials, it is too
extensive and time consuming for use in daily care in general
practice.
Because the items erythema, oedema, and excoriations
correlated well with the SCORAD, we conclude that imple-
menting these items in the TIS is a feasible choice.
Theinterobserveragreementbetweenthediﬀerentinten-
sity items showed a wide range of diﬀerences, therefore these
items alone cannot be used to determine the severity of AD.
In contrast to previous studies [6, 15], the item “extent”
(of the SCORAD) showed good agreement between all
our observers. Furthermore, we found a good correlation
between the SCORAD and the item “extent.” An explanation
for this good correlation could be the fact that children who
visit a GP for their eczema in general have a mild form ofDermatology Research and Practice 5
eczema.Theextentofthismildformiseasiertoscore,sinceit
isallinthesame(low)range.TheextentofADisnotassessed
in the TIS; its addition could provide additional information
about the severity of AD in children who visit the GP for
eczema.
4.1. Limitations of the Present Study. A weakness of this
study is that, because we included patients who had already
received treatment for AD, the severity of their AD was
probably diminished at the time of the ﬁrst visit (several
days/weeks after the visit to the GP). Nevertheless, when
comparing AD complaints assessed during the ﬁrst and
second visit, a decrease in these complaints was observed at
the second visit. This indicates that AD complaints during
the ﬁrst visit were determined during a period with fair
complaints of AD.
Because of the mild distribution of the severity of AD
in our study population, it is diﬃcult to predict whether
our results (e.g., interobserver agreements and correlations)
are comparable with results in other populations. The
interobserver agreement between the three observers was
only available for a relatively small sample; therefore, these
results should be considered with caution. The interobserver
agreement between the two observers could be calculated for
a much larger sample size.
4.2. Conclusion. In conclusion, the TIS is an easy and fast
scoring system. Because of the moderate-to-good interob-
serveragreementandthehighcorrelationwiththeSCORAD,
werecommendthattheTISbeusedtodeterminetheseverity
of AD in general practice.
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